High circulating levels of sICAM-1 and sVCAM-1 in the patients with Hashimoto’s thyroiditis
- 1 July 2016
- journal article
- research article
- Published by Taylor & Francis in Endocrine Research
- Vol. 42 (2) , 110-116
Abstract
Objective: To investigate whether soluble intercellular adhesion molecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) levels are increased in euthyroid patients with Hashimoto’s thyroiditis (HT) and whether they are associated with thyroid autoimmunity and metabolic parameters. Design: Cross-sectional. Subjects and Methods: In total, 80 euthyroid patients with HT and 80 age- and body mass index (BMI)-matched control participants were included. Serum sICAM-1, sVCAM-1, free triiodothyronine (fT3), free thyroxine (fT4), thyroid-stimulating hormone (TSH), thyroid peroxidase antibody (anti-TPO), thyroglobulin antibody (anti-TG), fasting blood glucose (FBG), insulin, and lipid levels and homeostasis model assessment for insulin resistance (HOMA-IR) were assessed in all participants. Results: The patients with HT had significantly higher levels of sICAM-1 and sVCAM-1 than controls (both p < 0.001). The difference was sustained after adjustment for TSH and levothyroxine use. Regression analysis demonstrated that sICAM-1 was related to anti-TPO (p < 0.001), and sVCAM-1 was related to both anti-TPO and-TG (p < 0.001 and p = 0.03, respectively); this relationship was sustained after adjustment for age and BMI. Although FBG and HOMA-IR were higher in the HT group, logistic regression analysis revealed that there was no effect of anti-TPO, anti-TG, sICAM-1, sVCAM-1, and C-reactive protein (CRP) on the occurrence of high FBG and high HOMA-IR. Conclusion: sICAM-1 and sVCAM-1 levels were significantly elevated in the patients with euthyroid HT and correlated closely with thyroid autoimmunity. However, soluble adhesion molecules had no relation with glucose metabolism parameters in the HT patients.Keywords
This publication has 31 references indexed in Scilit:
- Serum levels of adhesion molecules ICAM-1 and VCAM-1 and tissue inhibitor of metalloproteinases, TIMP-1, are elevated in patients with autoimmune thyroid disorders: Relevance to vascular inflammationNutrition, Metabolism and Cardiovascular Diseases, 2011
- Effects of Octreotide Treatment on Graves' Ophthalmopathy and Circulating sICAM-1 LevelsThyroid®, 1996
- Expression of intercellular adhesion molecules 1 (ICAM-1) via an osmotic effect in human umbilical vein endothelial cells exposed to high glucose mediumLife Sciences, 1996
- Soluble Intercellular Adhesion Molecule-1 Concentrations in Patients with Subacute Thyroiditis and in Patients with Graves' Disease with or without Ophthalmopathy.Endocrine Journal, 1996
- Intercellular Adhesion Molecule-1 (ICAM-1) in the Sera of Patients with Graves' Disease: Correlation with Disease Activity and Treatment StatusThyroid®, 1995
- The Expression of Adhesion Molecules in Thyroid Glands from Patients with Graves' DiseaseThyroid®, 1994
- Soluble intercellular adhesion molecule-1 (sICAM-1) in sera of patients with Graves’ ophthalmopathy and thyroid diseasesClinical and Experimental Immunology, 1993
- Graves' immunoglobulins and cytokines stimulate the expression of intercellular adhesion molecule‐1 (ICAM‐1) in cultured Graves' orbital fibroblastsEuropean Journal of Clinical Investigation, 1992
- Adhesion molecule expression in Graves' thyroid glands; potential relevance of granule membrane protein (GMP-140) and intercellular adhesion molecule-1 (ICAM-1) in the homing and antigen presentation processesClinical and Experimental Immunology, 1992
- Expression of intercellular adhesion molecule-1 (ICAM-1) on human thyroid cell lines correlated with their binding of lymphoblastsMolecular and Cellular Endocrinology, 1990